Loading...
XNASICAD
Market cap52mUSD
Jan 08, Last price  
1.96USD
1D
-4.85%
1Q
41.01%
Jan 2017
-39.32%
Name

ICAD Inc

Chart & Performance

D1W1MN
XNAS:ICAD chart
P/E
P/S
3.00
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
8.95%
Rev. gr., 5y
-7.53%
Revenues
17m
-38.03%
23,308,46219,769,82219,721,35826,612,41237,491,54828,109,26524,575,03528,652,00028,275,00033,067,00043,924,00041,554,00026,338,00028,102,00025,621,00031,340,00029,698,00033,638,00027,944,00017,318,000
Net income
-5m
L-64.51%
-828,263-4,758,488-6,637,958-1,538,5324,356,189-1,967,624-6,223,963-37,587,000-9,374,000-7,608,000-1,009,000-32,447,000-10,099,000-14,256,000-9,017,000-13,551,000-17,610,000-11,245,000-13,656,000-4,847,000
CFO
-5m
L-61.19%
-1,950,038-1,296,584-4,411,002574,5699,777,9313,442,860207,328-10,142,000-4,204,000-1,424,0003,204,000-1,900,000-5,478,000-7,337,000-3,867,000-7,107,000-6,985,000-9,408,000-12,789,000-4,964,000
Earnings
Mar 10, 2025

Profile

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
IPO date
Dec 13, 1984
Employees
108
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
17,318
-38.03%
27,944
-16.93%
Cost of revenue
25,007
41,650
Unusual Expense (Income)
NOPBT
(7,689)
(13,706)
NOPBT Margin
Operating Taxes
20
(116)
Tax Rate
NOPAT
(7,709)
(13,590)
Net income
(4,847)
-64.51%
(13,656)
21.44%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,966
355
BB yield
-4.34%
-0.77%
Debt
Debt current
188
582
Long-term debt
734
6,188
Deferred revenue
974
542
Other long-term liabilities
Net debt
(20,748)
(14,558)
Cash flow
Cash from operating activities
(4,964)
(12,789)
CAPEX
(922)
(534)
Cash from investing activities
3,275
(534)
Cash from financing activities
2,046
355
FCF
(2,948)
(18,191)
Balance
Cash
21,670
21,313
Long term investments
15
Excess cash
20,804
19,931
Stockholders' equity
(271,418)
(266,582)
Invested Capital
306,270
305,411
ROIC
ROCE
EV
Common stock shares outstanding
25,613
25,202
Price
1.77
-3.28%
1.83
-74.58%
Market cap
45,335
-1.70%
46,120
-74.15%
EV
24,587
31,562
EBITDA
(7,280)
(13,185)
EV/EBITDA
Interest
16
10
Interest/NOPBT